These insider sales are small in proportion to market cap and directly follow vesting/tax-withholding events, reducing their informational content. No bearish signal. Continue to monitor for any cluster of open-market purchases or any material change in the company's pipeline or commercialization trajectory.
EXEL drugs
EXEL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 20 $49.89entry
- T+1 · 6mo ago −0.80%α −1.00% · $49.49
- T+5 · 6mo ago +3.15%α +1.34% · $51.46
- T+20 · 5mo ago +5.12%α +5.15% · $52.44
- T+60 · 3mo ago +2.71%α −2.02% · $51.24
Price Chart
How similar events traded
Executive Summary
Exelixis CFO and General Counsel sold a combined ~$2.08M in open-market shares on May 18, 2026, alongside a large non-cash gift of 124,047 shares by CEO Morrissey. The open-market sales amount to ~0.017% of the $12.5B market cap, well below materiality thresholds. The sales coincide with routine vesting-related tax withholding transactions by the same executives two days prior, suggesting the sales are liquidity-driven rather than informational.
Key Financial Metrics
Key Facts
- CFO Senner sold 34,901 shares at $50.00 for $1.75M on May 18
- General Counsel Hefti sold 6,625 shares at $50.21 for $332,641 on May 18
- CEO Morrissey gifted 124,047 shares at $0 on May 18 (non-cash transaction)
- Combined open-market sales of $2.08M represent ~0.017% of $12.5B market cap
- All five named executives had tax-withholding share surrenders on May 15, totaling ~$12.2M
- The May 18 sales follow May 15 vesting events by 1-2 business days, consistent with liquidity-driven sales
Financial Impact
Open-market sales of $2.08M vs $12.5B market cap, negligible (0.017%). C-suite cash-out value is immaterial relative to company size.
Risk Factors
- Insiders could accelerate selling if upcoming pipeline data disappoints
- CEO gift of 124K shares reduces his economic alignment, though gift recipients could sell
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-EXEL-1779231552582 |
Track record
16 reports on EXEL
0 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +21.97% at T+60 after the Feb 28, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20266d ago SC 13G Neutral 3/10 Entry $70.58 to $70.70 Now $67.10 −4.93% ▲ +0.17% −1.15% vs SPY
- Nov 9, 20266d ago SC 13D/A Bearish 5/10 Entry $70.58 to $70.70 Now $67.10 +4.93% ▼ −0.17% +1.15% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $69.39 to $70.13 Now $67.10 −3.30% ▲ +1.07% +1.55% vs SPY
- Oct 20, 202627d ago Institutional Cluster Neutral 2/10 Entry $64.58 to $65.31 Now $67.10 +3.90% ▲ +1.13% +2.31% vs SPY
- Oct 12, 20265w ago Institutional Cluster Neutral 3/10 Entry $59.82 to $59.51 Now $67.10 +12.17% ▼ −0.52% −0.51% vs SPY
- Sep 11, 20269w ago 8-K Bearish 6/10 Entry $56.12 to $56.21 Now $67.10 −19.57% ▼ −0.16% −0.61% vs SPY
- Jun 3, 202623w ago Insider Cluster Neutral 2/10 Entry $52.39 to $52.69 Now $67.10 +28.08% ▲ +0.57% +3.17% vs SPY
- May 29, 202624w ago 8-K Neutral 3/10 Entry $50.20 to $48.49 Now $67.10 +33.67% ▼ −3.41% −3.55% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers